无缝合瓣与经导管主动脉瓣在中危老年主动脉瓣狭窄患者中的多中心对比研究
该多中心研究纳入2008至2015年967例>75岁、STS评分4%-8%的重度主动脉瓣狭窄患者,倾向评分匹配后无缝合瓣组与经导管主动脉瓣植入组各291例。结果显示无缝合瓣组30天死亡率、永久起搏器植入率及5年卒中/TIA、瓣周漏≥II级、全因死亡和主要不良心血管事件发生率均显著低于经导管组。
要点
- 无缝合瓣组30天死亡率1.7%,显著低于经导管组的5.5%(P=.024)。
- 5年随访无缝合瓣组全因死亡率16.1%±4.1%,低于经导管组的28.9%±5.3%(P=.006)。
- 经导管主动脉瓣植入是5年死亡和主要不良心血管事件的独立预测因素。
核心结论
- 对于中危老年主动脉瓣狭窄患者,无缝合瓣相比经导管主动脉瓣植入改善了结局。
- 经导管主动脉瓣植入在该亚组人群中的应用需进一步随机对照试验评估。
研究设计与样本
- 多中心研究,纳入2008至2015年967例>75岁、STS评分4%-8%的孤立性主动脉瓣狭窄患者。
- 无缝合瓣组481例,经导管主动脉瓣植入组486例;倾向评分匹配后每组291例。
主要发现
- 匹配后30天死亡率无缝合瓣组1.7% vs 经导管组5.5%(P=.024)。
- 永久起搏器植入率无缝合瓣组5.5% vs 经导管组10.7%(P=.032)。
- 5年卒中/短暂性脑缺血发作累积发生率无缝合瓣组1.4% vs 经导管组5.3%(P=.010)。
- 瓣周漏≥II级发生率无缝合瓣组1.3% vs 经导管组9.8%(P<.001)。
- 60个月随访全因死亡率无缝合瓣组16.1%±4.1% vs 经导管组28.9%±5.3%(P=.006),主要不良心血管事件率23.5%±4.1% vs 39.0%±5.6%(P=.002)。
关键数值与推荐
- 多变量Cox回归显示经导管主动脉瓣植入是5年死亡的独立预测因素(HR 1.86,CI 1.09-3.18,P=.022)。
- 经导管主动脉瓣植入是主要不良心血管事件的独立预测因素(HR 1.73,CI 1.13-2.73,P=.010)。
临床怎么用
- 在中危老年主动脉瓣狭窄患者中,选择无缝合瓣可能降低早期死亡、起搏器植入及远期不良事件风险。
- 经导管主动脉瓣植入在该人群中的应用应谨慎,需进一步随机对照试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This multi-institutional study compares the long-term outcome of elderly patients with severe aortic stenosis and an intermediate risk profile undergoing sutureless versus transcatheter aortic valve implantation. METHODS: From 2008 to 2015, 967 elderly patients (>75 years) with intermediate risk (Society of Thoracic Surgeons score 4%-8%) and isolated aortic stenosis were included in the study (sutureless valve = 481; transcatheter aortic valve implantation = 486). After propensity score matching, 2 matched groups of 291 patients were obtained. Transcatheter valves implanted in patients were the CoreValve (Medtronic, Minneapolis, Minn), Edwards SAPIEN-XT (Edwards Lifesciences, Irvine, Calif), and Acurate-TA (Symetis, Lausanne, Switzerland). Primary end points included all-cause death at 30 days and 5 years. Secondary end points included early and 5-year incidence of composite adverse events (major adverse cardiovascular events: all-cause death, stroke, pacemaker implant, myocardial infarction, paravalvular leak ≥II, and reoperation). RESULTS: After matching, there were no substantial differences between groups. The 30-day mortality was significantly lower in the sutureless valve group (sutureless valve = 1.7% vs transcatheter aortic valve implantation = 5.5%; P = .024) and the rate of permanent pacemaker implantation (sutureless valve = 5.5% vs transcatheter aortic valve implantation = 10.7%, P = .032). Stroke/transient ischemic attack cumulative incidence at 5 years was 1.4% in the sutureless valve group and 5.3% in the transcatheter aortic valve implantation group (P = .010). The incidence of perivalvular leak grade II or greater was 1.3% in the sutureless valve group and 9.8% in the transcatheter aortic valve implantation group (P < .001). At 60 months follow-up, the all-cause death rate was lower in the sutureless valve group than in the transcatheter aortic valve implantation group (sutureless valve = 16.1% ± 4.1% vs transcatheter aortic valve implantation = 28.9% ± 5.3%, P = .006), and the major adverse cardiovascular event rate was lower in the sutureless valve group (sutureless valve = 23.5% ± 4.1% vs transcatheter aortic valve implantation = 39.0% ± 5.6%, P = .002). Multivariable Cox regression identified transcatheter aortic valve implantation as an independent predictor for 5-year mortality and major adverse cardiovascular events (hazard ratio, 1.86; confidence interval, 1.09-3.18; P = .022) (hazard ratio, 1.73; confidence interval, 1.13-2.73; P = .010). CONCLUSIONS: Sutureless valves improved the outcomes of aortic stenosis in elderly patients with an intermediate risk profile when compared with transcatheter aortic valve implantation. The use of transcatheter aortic valve implantation in this subset population should be evaluated in further controlled randomized trials with sutureless valve use in a comparative cohort.
引用
- Muneretto C, Solinas M, Folliguet T, et al. Sutureless versus transcatheter aortic valves in elderly patients with aortic stenosis at intermediate risk: A multi-institutional study. J Thorac Cardiovasc Surg. 2020. PMID: 32727681. doi:10.1016/j.jtcvs.2020.04.179
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。